ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2624

Preliminary Content Validation of the Patient Reported Outcomes Measurement Information System (PROMIS) Short Forms in People Living with Rheumatoid Arthritis

Anna Kristina Gutierrez1, Michelle Jones2, Susan J. Bartlett1,3,4 and Clifton O. Bingham III2, 1Division of Rheumatology, Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, 4Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: patient-reported outcome measures and rheumatoid arthritis (RA), PRO, PROMIS

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The process of patient reported outcome (PRO) validation requires demonstration that the concept being measured and the patient experience of the corresponding symptom or impact are aligned. The NIH Patient Reported Outcomes Measurement Information System (PROMIS) provides standardized measures across the illness continuum of domains of physical, mental, and social health. Whether items contained within PROMIS item banks and short forms (SF) are felt to be relevant to people living with rheumatoid arthritis (RA) has not been previously reported.

Methods: We administered surveys to RA patients (pts) seen for routine care in an academic rheumatology practice. Routine clinical (MD global, joint count, pt global, pain, and fatigue VAS) and demographic data were collected. Surveys included PROMIS SFs for Physical Function (PF) 20a; Pain Interference (PI) 8a, Fatigue 7a and 8a, Ability to Participate in Social Roles and Activities 8a (PSRA), and Depression 8a. Pts also completed the PROMIS Profile 29 v 2.0, which contains 4 item assessments for these domains. For each domain, patients rated the relevance of items within the SF to their disease experience and the importance of the symptom to their disease.  We also queried how much patients were able to separate their overall symptom experience from that due to RA (e.g., “How much of your fatigue is due to your RA?”). Mean PROMIS T-scores were calculated.

Results: Fifty two pts (86.5% female, 88.5% Caucasian, 31% HS education or less) were surveyed with a mean (SD) age of 52.5 (13.5) yrs, disease duration of 14.7 (11.4) yrs, and CDAI 9.7 (15). PROMIS T-scores were similar using SF of different lengths, though the magnitude of difference was greatest for the PF measures. RA patients had worse PF, PI, and Fatigue that exceeded 0.4SD from the general population norm of 50 (Table 1).  More than 60% of respondents reported that the SF items in a domain completely or mostly reflected their experience due to their RA. For PF and PSRA almost half of patients considered both their symptom in general and their symptom due to RA when answering items (55.8 and 48.1%). When answering items on PI, 51.9% were thinking only of their RA. However, most (>88 %) would not have responded differently to the questions if instead asked “due to their RA”.  Most patients attribute problems with PF and PI to their RA, but not problems with sleep, emotional health, or PSRA. Most patients (>75%) considered all domains very important. Almost all (>85%) did not feel that additional questions needed to be asked regarding these symptoms.

Conclusion: These results provide preliminary evidence of the content validity in terms of importance and relevance of selected PROMIS domains and SF items from the perspective of people living with RA. Additional studies in a broader group of pts are needed.

Table 1. PROMIS short form T-scores for each domain.

Domain/Symptom

Short   Form

Physical Function (PF)

4a

20a

43.9 (10.2)

41.9 (11.5)

Pain Interference (PI)

4a

8a

56.3 (9.8)

55.9 (9.9)

Fatigue

4a

7a

8a

54.1 (13.4)

54.5 (11.3)

54.5 (13.5)

Ability to Participate in Social   Roles and Activities (PSRA)

4a

8a

48.9 (10.5)

48.8 (11.1)

Depression

4a

8a

51.1 (10.7)

50.2 (11.5)

Anxiety 4a

50.3 (10.5)

Sleep 4a

51.4 (9.8)

Legacy PROs

Mean (SD)

Patient Global VAS

34 (29.9)

Pain VAS

3.8 (3.5)

Fatigue VAS

4.5 (4)


Disclosure: A. K. Gutierrez, None; M. Jones, None; S. J. Bartlett, PCORI, 2; C. O. Bingham III, NIH, 2,PCORI, 2.

To cite this abstract in AMA style:

Gutierrez AK, Jones M, Bartlett SJ, Bingham CO III. Preliminary Content Validation of the Patient Reported Outcomes Measurement Information System (PROMIS) Short Forms in People Living with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/preliminary-content-validation-of-the-patient-reported-outcomes-measurement-information-system-promis-short-forms-in-people-living-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/preliminary-content-validation-of-the-patient-reported-outcomes-measurement-information-system-promis-short-forms-in-people-living-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology